The treatment of advanced carcinoma of the bladder with combination chemotherapy.
Thirty patients with advanced T4 transitional cell carcinoma of the bladder were treated in a prospective randomised trial with combination chemotherapy. Sixteen patients received cyclophosphamide, doxorubicin (Adriamycin) and 5-fluorouracil, whilst 14 patients received methotrexate, doxorubicin and 5-fluorouracil with folinic acid rescue. There were no complete or partial responses to either regime and there was progression in all patients. The 2 regimes were shown to be relatively non-toxic but failed to alter the natural course of the disease.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011897:Random Allocation; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate